Cargando…

ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer

Worldwide, lung cancer accounts for approximately 1 million deaths each year, making it the most common cause of cancer-related mortality. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases and is often associated with a relatively poor prognosis. The majority of...

Descripción completa

Detalles Bibliográficos
Autores principales: Allingham-Hawkins, Diane, Lea, Andrew, Levine, Susan
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2998231/
https://www.ncbi.nlm.nih.gov/pubmed/21152077
http://dx.doi.org/10.1371/currents.RRN1202
_version_ 1782193348017127424
author Allingham-Hawkins, Diane
Lea, Andrew
Levine, Susan
author_facet Allingham-Hawkins, Diane
Lea, Andrew
Levine, Susan
author_sort Allingham-Hawkins, Diane
collection PubMed
description Worldwide, lung cancer accounts for approximately 1 million deaths each year, making it the most common cause of cancer-related mortality. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases and is often associated with a relatively poor prognosis. The majority of NSCLC patients present with advanced disease and have an average 5-year survival rate of 5%. Currently, the standard of care for NSCLC includes treatment with a platinum-based chemotherapy regimen. However, not all patients benefit equally from such treatment. Therefore, recent pharmacogenomic studies have been performed in order to identify specific biomarkers that may allow for patient-tailored treatment strategies. One such biomarker is expression of the excision repair cross-complementation group 1 protein, ERCC1.
format Text
id pubmed-2998231
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-29982312010-12-08 ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer Allingham-Hawkins, Diane Lea, Andrew Levine, Susan PLoS Curr Evidence on Genomic Tests Worldwide, lung cancer accounts for approximately 1 million deaths each year, making it the most common cause of cancer-related mortality. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases and is often associated with a relatively poor prognosis. The majority of NSCLC patients present with advanced disease and have an average 5-year survival rate of 5%. Currently, the standard of care for NSCLC includes treatment with a platinum-based chemotherapy regimen. However, not all patients benefit equally from such treatment. Therefore, recent pharmacogenomic studies have been performed in order to identify specific biomarkers that may allow for patient-tailored treatment strategies. One such biomarker is expression of the excision repair cross-complementation group 1 protein, ERCC1. Public Library of Science 2010-12-06 /pmc/articles/PMC2998231/ /pubmed/21152077 http://dx.doi.org/10.1371/currents.RRN1202 Text en http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Evidence on Genomic Tests
Allingham-Hawkins, Diane
Lea, Andrew
Levine, Susan
ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer
title ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer
title_full ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer
title_fullStr ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer
title_full_unstemmed ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer
title_short ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer
title_sort ercc1 expression analysis to guide therapy in non-small cell lung cancer
topic Evidence on Genomic Tests
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2998231/
https://www.ncbi.nlm.nih.gov/pubmed/21152077
http://dx.doi.org/10.1371/currents.RRN1202
work_keys_str_mv AT allinghamhawkinsdiane ercc1expressionanalysistoguidetherapyinnonsmallcelllungcancer
AT leaandrew ercc1expressionanalysistoguidetherapyinnonsmallcelllungcancer
AT levinesusan ercc1expressionanalysistoguidetherapyinnonsmallcelllungcancer